ALNYLAM PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Deferred Income Tax Expense (Benefit) of $11.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$27.17M.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $5.60M.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $9.73M, a 2763.24% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was $9.64M, a 2023.13% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was -$2.20M.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was -$106.76M.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was -$713.00K.
- ALNYLAM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was -$1.43M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.97M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | -$27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$21.57M derived: sum of 2 quarters · filed 2026-02-12 | -$11.84M derived: sum of 3 quarters · filed 2026-07-30 | -$2.20M 10-K · filed 2026-02-12 |
| 2025-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $15.33M derived: sum of 2 quarters · filed 2026-07-30 | $24.97M 10-Q · filed 2025-10-30 | -$82.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $9.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $19.37M 10-Q · filed 2026-07-30 | -$88.02M derived: sum of 3 quarters · filed 2026-07-30 | -$88.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.64M 10-Q · filed 2025-05-01 | -$97.75M derived: sum of 2 quarters · filed 2026-02-12 | -$97.92M derived: sum of 3 quarters · filed 2026-02-12 | -$97.58M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$107.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$107.56M derived: sum of 2 quarters · filed 2026-02-12 | -$107.22M derived: sum of 3 quarters · filed 2026-02-12 | -$106.76M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $177.00K derived: sum of 2 quarters · filed 2025-10-30 | $631.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $794.00K 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $454.00K 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$713.00K 10-K · filed 2026-02-12 | |||
| 2022-12-31 | -$1.43M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | -$2.77M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | -$3.22M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | -$1.98M 10-K · filed 2022-02-10 | |||
| 2018-12-31 | -$788.00K 10-K · filed 2021-02-11 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2010-06-30 | -$144.00K 10-Q · filed 2010-08-05 | |||
| 2009-06-30 | -$250.00K 10-Q · filed 2010-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |